Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Sanara MedTech Q3 2026 Results: Net Loss of $1.41M, Loss Narrows

Sanara MedTech reported net revenue of $84.4 million for the nine months ended September 30, 2026, a 12% increase over the prior year. Despite higher gross profits, the company recorded a net loss of $1.4 million for the period, primarily due to increased selling, general, and administrative expenses and interest costs.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue28.426.3
Gross profit26.324.5
Net income-1.4-30.4

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+8.0%
Gross margin92.6%
Operating margin2.6%
Source

10-Q filed with the SEC, NASDAQ: SMTI. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Sanara MedTech Inc.: key numbers

Share price
$32.76Close, Nov 16
Market cap
$301M
Shares outstanding
9.18MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Orthopedic, Prosthetic & Surgical Appliances & SuppliesSIC 3842

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Sanara MedTech Inc.

All →
4:11 PM ET 8-K
Financial Results

Sanara MedTech Financial Results

Sanara MedTech reported Q3 2026 net revenue of $28.4 million, an 8% increase year-over-year, and Adjusted EBITDA of $5.6 million. The company recorded a net loss from continuing operations of $1.3 million, which included $3.0 million in legal and advisory costs related to its pending merger with MiMedx Group, Inc.

Term
Q3 2026
4:16 PM ET 8-K
Divestiture

Sanara MedTech Divestiture for $2M

Sanara MedTech Inc. sold all assets of its wholly owned subsidiary, Tissue Health Plus, LLC (THP), to an unrelated third party. The transaction included THP's business software products and intellectual property for approximately $2.0 million plus certain earnout rights.

Value
$2M
9:21 AM ET 8-K
M&A Deal

Sanara MedTech M&A Deal with MiMedx Group, Inc.

Sanara MedTech and MiMedx Group received a 'Second Request' for information from the FTC regarding their pending merger. This request extends the HSR Act waiting period until 30 days after both parties substantially comply with the request, unless terminated earlier by the FTC.

Counterparty
MiMedx Group, Inc.
6:05 AM ET 8-K
M&A Deal

Sanara MedTech M&A Deal with MiMedx Group, Inc.

Sanara MedTech shareholders approved the previously announced merger agreement with MiMedx Group, Inc., under which Sanara will become a wholly-owned subsidiary of MiMedx. The filing also provides a regulatory update noting that MiMedx voluntarily withdrew its HSR Act notification to allow the FTC additional time for review. The merger remains subject to customary closing conditions.

Counterparty
MiMedx Group, Inc.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.